ArriVent BioPharma Files 8-K Report

Ticker: AVBP · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1868279

Arrivent Biopharma, INC. 8-K Filing Summary
FieldDetail
CompanyArrivent Biopharma, INC. (AVBP)
Form Type8-K
Filed DateJul 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

ArriVent BioPharma filed an 8-K on 7/21/25, check for updates.

AI Summary

On July 21, 2025, ArriVent BioPharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates that ArriVent BioPharma, Inc. has submitted a current report to the SEC, which may contain updates on significant company events or financial information.

Risk Assessment

Risk Level: low — The filing is a standard 8-K submission and does not disclose any immediate risks or negative events.

Key Players & Entities

FAQ

What specific "Other Events" are reported by ArriVent BioPharma, Inc. in this 8-K filing?

The provided text for the 8-K filing lists "Other Events" as an item information, but does not specify the nature of these events.

What is the significance of the filing date July 21, 2025?

July 21, 2025, is the date of the earliest event reported in the 8-K filing by ArriVent BioPharma, Inc.

Where are ArriVent BioPharma, Inc.'s principal executive offices located?

ArriVent BioPharma, Inc.'s principal executive offices are located at 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073.

What is the SEC file number for ArriVent BioPharma, Inc.?

The SEC file number for ArriVent BioPharma, Inc. is 001-41929.

What is the SIC code for ArriVent BioPharma, Inc.?

The Standard Industrial Classification (SIC) code for ArriVent BioPharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding ArriVent BioPharma, Inc. (AVBP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing